Frontage Clinical Services, Inc. Expands Facilities to Accommodate Tobacco and Nicotine-Related Studies

Frontage Clinical Services Inc. (“Frontage Clinical”) announced today the implementation of ClinSpark®, a web-based eSource platform, that supports activities from subject recruitment through database lock. This versatile, automated solution to paper-based documentation was developed specifically for Phase I clinical trials by Foundry Health, LLC.

Frontage Holdings Corporation ( “Frontage” or the “Group”, 1521.HK), a contract research organization (“CRO”) providing integrated, science-driven research, analytical and development services with presence in both the United States and China, today announced Frontage Laboratories, Inc.("Frontage Labs"), a wholly-owned subsidiary of the Group, entered into an equity purchase agreement with Dr. Phillip Tiller and Dr. Xiao (Sean) Yu, two independent third party individuals. According to the agreement, Frontage Labs will purchase the entire equity interest in RMI Laboratories, LLC (“RMI”) owned by the individual third parties.

Hong Kong, China. October 25, 2019 - Frontage Holdings Corporation ( “Frontage Holdings” or “the Group”, 1521.HK), a contract research organization (“CRO”) providing integrated, science-driven research, analytical and development services with presence in both the United States and China, today announced Frontage Laboratories (Shanghai) Co., Ltd.("Frontage Shanghai"), an indirectly wholly-owned subsidiary of the Group, entered into the stock transfer agreement with an independent third party individual. According to the agreement, Frontage Shanghai will acquire 25.96% stake in Frontage Laboratories (Suzhou) Co, Ltd. (“Frontage Suzhou”) owned by the individual third party for a cash consideration of RMB 14,433,800. Upon the completion of the Acquisition, Frontage Shanghai will own a 75% stake in Frontage Suzhou. As a result, Frontage Suzhou will become a subsidiary of the Group with an indirect 75% equity. Therefore, Frontage Suzhou’s financial results, assets and liabilities will be consolidated into the Group's financial statements.

Frontage Laboratories, Inc, a CRO providing integrated, science-driven, product development services, is pleased to announce expansion of their bioanalytical laboratories. The extension of their US bioanalytical laboratories in Exton PA includes an additional 10,000 square feet of laboratory space that will be dedicated to further enhancement of their capabilities in biologic drug development, biomarkers and cell and gene therapy.